[vc_row content_width=”grid” css=”.vc_custom_1516178432909{padding-top: 80px !important;padding-bottom: 80px !important;}”][vc_column offset=”vc_col-lg-5 vc_col-md-12″][vc_single_image image=”7179″ img_size=”full”][\/vc_column][vc_column offset=”vc_col-lg-7 vc_col-md-12″ css=”.vc_custom_1516178424937{padding-right: 50px !important;padding-left: 50px !important;}”][vc_empty_space height=”25px”][vc_column_text]Dr. Rick Xu is Chief Medical Officer of Oricell Therapeutics. Dr. Xu joined Quan as venture partner since 2021, and have advised and served as interim CMO to multiple of Quan\u2019s portfolio companies. Prior to Quan, Dr. Xu was the founding Chief Medica Officer of InnoCare Pharma (HKEX: 09969). Over the past ~30 years, Dr. Xu has built his career in global clinical development through his tenue at Roche \/ Genentech, Pfizer, and Sterling Winthrop. While he has extensive experience in Immuno-oncology, Oncology, CNS, virology and infectious diseases with numerous IND and NDA filings, he\u2019s most known for successfully developed two blockbuster drugs PEGSYS and the long Acting Filgrastim. Dr. Xu is a frequent presenter at national \/ international conferences, and serves as an advisor \/ consultant to many academic institutions and non-profit professional organizations.<\/p>\n
<\/p>\n
Dr. Xu received his medical degree from Harbin Medical University, and his fellowship training in Gastroenterology at Truman Medical Center in Kansas City. He also has a Ph.D. in Biopharmaceuticals from SUNY at Buffalo.[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n","protected":false},"excerpt":{"rendered":"
[vc_row content_width=”grid” css=”.vc_custom_1516178432909{padding-top: 80px !important;padding-bottom: 80px !important;}”][vc_column offset=”vc_col-lg-5 vc_col-md-12″][vc_single_image image=”7179″ img_size=”full”][\/vc_column][vc_column offset=”vc_col-lg-7 vc_col-md-12″ css=”.vc_custom_1516178424937{padding-right: 50px !important;padding-left: 50px !important;}”][vc_empty_space height=”25px”][vc_column_text]Dr. Rick Xu…<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":6552,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"full-width.php","meta":{"footnotes":""},"_links":{"self":[{"href":"https:\/\/cn.quancapital.com\/en\/wp-json\/wp\/v2\/pages\/7178"}],"collection":[{"href":"https:\/\/cn.quancapital.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/cn.quancapital.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/cn.quancapital.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cn.quancapital.com\/en\/wp-json\/wp\/v2\/comments?post=7178"}],"version-history":[{"count":7,"href":"https:\/\/cn.quancapital.com\/en\/wp-json\/wp\/v2\/pages\/7178\/revisions"}],"predecessor-version":[{"id":8518,"href":"https:\/\/cn.quancapital.com\/en\/wp-json\/wp\/v2\/pages\/7178\/revisions\/8518"}],"up":[{"embeddable":true,"href":"https:\/\/cn.quancapital.com\/en\/wp-json\/wp\/v2\/pages\/6552"}],"wp:attachment":[{"href":"https:\/\/cn.quancapital.com\/en\/wp-json\/wp\/v2\/media?parent=7178"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}